# Optimizing Influenza Vaccine Allocation

#### Jan Medlock

Department of Biomedical Sciences Oregon State University jan.medlock@oregonstate.edu


7 March 2013





## Influenza

- Annual seasonal flu
- Rare epidemic or pandemic flu

Introduction •0000







Introduction

#### Influenza in the US

- 30k deaths annually
- \$90B in lost productivity annually
- 120M+ vaccine doses produced annually for seasonal flu
  - Around 85M typically used
- Vaccine production is poor for new pandemic flus
  - 2009 H1N1: less than 20M doses available prior to peak
- 300M population

#### 2009 H1N1 Influenza



The guarantine will end Friday, and the students are scheduled to return to the United States on Mike Kennedy, the head of Barrie School, said U.S. consular officials have since told the school

Guizhou province city in southern China.

Sunday, Temple said.

# H5N1 Bird Flu

#### 447 cases and 263 deaths!



Kiphail, M.D. Wattona Auwenit, Ph.D., Pilaipan Puthavuthone, Ph.D. Mongkol Ujprasertkul, M.D. Kohporn Boonnak, M.S., Chakraret Pitaywonganon, M.D., Amey J. Cos., Ph.D., Sherif, R. Soik, M.D., Ph.D., Pranee Thawatsupha, M.S., Malinee Chittaganpitie, B.Sc., Redjan Khontong, M.D., James M. Simmerman, R.N., M.S., and Supamit Chinesatthiwat. M.D. M.P.H.





# Problem Setup

#### Optimizing Influenza Vaccine Distribution

lan Medlock 1,2x and Alison P. Galvani 1


The criteria to assess public health policies are fundamental to policy optimization. Using a model parametrized with survey-based contact data and mortality data from influenza pandemics, we determined optimal vaccine allocation for five outcome measures: deaths, infections, years of life lost, contingent valuation, and economic costs. We find that optimal vaccination is achieved by prioritization of schoolchildren and adults aged 30 to 39 years. Schoolchildren are most responsible for transmission, and their parents serve as bridges to the rest of the population. Our results indicate that consideration of age-specific transmission dynamics is paramount to the optimal allocation of influenza vaccines. We also found that previous and new recommendations from the U.S. Centers for Disease Control and Prevention both for the novel swine-origin influenza and, particularly, for seasonal influenza, are suboptimal for all outcome measures,

Taccination is the principal strategy for re- 20% for those aged 5 to 19, 17% for those aged ducing the disease burden of many in- 20 to 49, 35% for those aged 50 to 64, and 63% fectious diseases. The evaluation of for those older than 64 years (fig. \$15), totaling the antigenic evolution of influenza. In addition, zoonosis can lead to the emergence of influenza subtypes, such as the novel swine-origin influenza virus. Consequently, manufacturing of influenza vaccine follows a tight schedule to achieve sufficient doses (24). This schedule is also vulnerable to disruptions, as evidenced by the vaccine contamination that left the United States short on doses in 2004 to 2005 (25). The World Health Organization recently announced that the unusually slow growth of swine-origin H1N1 in chicken eggs may cause shortfalls in current production of vaccine this year (26). When vaccine availability is limited or when vaccine efficacy is low, optimal allocation of vaccines is imperative. Nonetheless, vaccine allocation can also be improved when vaccine is plentiful and highly efficacious. We evaluated current vaccine allocation policies based on the optima derived from multiple outcome measures. We also compared the outcome measures

Medlock & Galvani, 2009, Science, 325: 1705-1708.

- How to distribute limited vaccine doses?
- Age structure but not risk or occupation

#### Model



Age structured  $(0, 1-4, 5-9, 10-14, 15-19, \dots, 70-74, 75+)$ No birth or natural death


## Model

$$\begin{split} \frac{\mathrm{d} U_{\mathrm{S}a}}{\mathrm{d} t} &= -\lambda_a U_{\mathrm{S}a} & \frac{\mathrm{d} V_{\mathrm{S}a}}{\mathrm{d} t} = -(1-\epsilon_a)\lambda_a V_{\mathrm{S}a} \\ \frac{\mathrm{d} U_{\mathrm{E}a}}{\mathrm{d} t} &= \lambda_a U_{\mathrm{S}a} - \tau U_{\mathrm{E}a} & \frac{\mathrm{d} V_{\mathrm{E}a}}{\mathrm{d} t} = (1-\epsilon_a)\lambda_a V_{\mathrm{S}a} - \tau V_{\mathrm{E}a} \\ \frac{\mathrm{d} U_{\mathrm{I}a}}{\mathrm{d} t} &= \tau U_{\mathrm{E}a} - (\gamma + \nu_{\mathrm{U}a})U_{\mathrm{I}a} & \frac{\mathrm{d} V_{\mathrm{I}a}}{\mathrm{d} t} = \tau V_{\mathrm{E}a} - (\gamma + \nu_{\mathrm{V}a})V_{\mathrm{I}a} \\ \frac{\mathrm{d} U_{\mathrm{R}a}}{\mathrm{d} t} &= \gamma U_{\mathrm{I}a} & \frac{\mathrm{d} V_{\mathrm{R}a}}{\mathrm{d} t} = \gamma V_{\mathrm{I}a} \end{split}$$

$$\lambda_{a} = \sum_{\alpha=1}^{17} \frac{\phi_{a\alpha} \sigma_{a} \beta_{\alpha} \left( U_{I\alpha} + V_{I\alpha} \right)}{N}$$

Age groups  $a=1,2,3,4,5,\ldots,16,17$  are ages  $0,1-4,5-9,10-14,15-19,\ldots,70-74,75+.$ 


# Case Mortality




Sources: Serfling, Sherman, Houseworth, 1967, Am J Epidemiol; Luk, Gross, Thompson, 2001, Clin Infect Dis; Glezen, 1996, Epidemiol Rev; Presanis et al, 2009, PLoS Med.

# Contacts

#### Mossong et al, 2008, PLoS Med




#### Model Infections without Vaccine



# **Objective Functions**

- Total Infections
- Total Deaths
- Years of Life Lost
- Total Cost
- Contingent Valuation



Find  $p_1, p_2, \cdots, p_{17}$  that minimizes

$$bN_{\mathrm{V}} + \sum \left( c_{\mathrm{U}a} N_{\mathrm{UI}a} + c_{\mathrm{V}a} N_{\mathrm{VI}a} + d_a N_{\mathrm{D}a} \right),$$

subject to


$$0 \le p_a \le 1,$$
  $N_V = \sum_a p_a N_a(0) \le Y,$   $U_{Sa}(0) = (1 - p_a) N_a(0),$   $V_{Sa}(0) = p_a N_a(0),$ 

$$N_{{\rm UI}a} = U_{{\rm S}a}(0) - U_{{\rm S}a}(T), \quad N_{{\rm VI}a} = V_{{\rm S}a}(0) - V_{{\rm S}a}(T), \quad N_{{\rm D}a} = N_a(0) - N_a(T),$$


$$\begin{split} \frac{\mathrm{d} U_{\mathrm{S}a}}{\mathrm{d} t} &= -\lambda_a U_{\mathrm{S}a}, & \frac{\mathrm{d} U_{\mathrm{E}a}}{\mathrm{d} t} &= \lambda_a U_{\mathrm{S}a} - \tau U_{\mathrm{E}a}, & \frac{\mathrm{d} U_{\mathrm{I}a}}{\mathrm{d} t} &= \tau U_{\mathrm{E}a} - (\gamma + \nu_{\mathrm{U}a}) U_{\mathrm{I}a}, & \frac{\mathrm{d} U_{\mathrm{R}a}}{\mathrm{d} t} &= \gamma U_{\mathrm{I}a}, \\ \frac{\mathrm{d} V_{\mathrm{S}a}}{\mathrm{d} t} &= -(1 - \epsilon_a) \lambda_a V_{\mathrm{S}a}, & \frac{\mathrm{d} V_{\mathrm{E}a}}{\mathrm{d} t} &= (1 - \epsilon_a) \lambda_a V_{\mathrm{S}a} - \tau V_{\mathrm{E}a}, & \frac{\mathrm{d} V_{\mathrm{I}a}}{\mathrm{d} t} &= \tau V_{\mathrm{E}a} - (\gamma + \nu_{\mathrm{V}a}) V_{\mathrm{I}a}, & \frac{\mathrm{d} V_{\mathrm{R}a}}{\mathrm{d} t} &= \gamma V_{\mathrm{I}a}, \end{split}$$

$$\lambda_{\mathfrak{d}} = \sum \frac{\phi_{\mathfrak{d}\alpha} \sigma_{\mathfrak{d}} \beta_{\alpha} \left( U_{I\alpha} + V_{I\alpha} \right)}{N} \, .$$


## Whom to Vaccinate?



# Whom to Vaccinate?




# Much Better than Other Strategies



# Uncertainty & Sensitivity Analysis


- Same model, with risk groups
- Build parameter distributions from literature
- Sample from these distributions and then optimize
- Analyze...

#### Parameter Distributions




## 80M Vaccine Doses

No Vaccine for Ages 45+!



# Big Improvement



# Importance of Parameters

Most important determinants of vaccine allocation:


- 1a. Recovery rate in ages 0–14
- **1b**. Recovery rate in ages 15+
  - 2.  $R_0$
  - 3. Vaccine efficacy vs. infection

from both Sensitivity Index and Partial Rank Correlation Coefficient.


Policymakers not just interested in one objective

- Multi-Objective Optimization finds Pareto sets
  - No objective can be improved without worsening another

# Minimizing Infections & Deaths



# Minimizing Infections & Deaths



# Multi-Objective Optimization

- Very slowly working up to 6 objectives
- Probably lots of similarity will reduce complexity

- For a fixed vaccine allocation
  - Sample from parameter distributions
  - Run model
  - Aggregate for a distribution of outcomes
- Simultaneously optimize multiple statistics of outcomes:
  - Median outcome
  - Worst case (e.g. upper 95% quantile)
- Another multi-objective problem!

#### Conclusions

- Can improve vaccination policies substantially
- Can incorporate uncertainty & multiple objectives
- Also working with NDSSL at Virginia Tech to understand differences in optimal distribution in network models
- Problems:
  - Huge uncertainty for pandemic influenza
  - Timing of vaccine availability
  - Societal optimum vs. Individual optimum
  - Parental resistance to vaccination

#### Thanks!

- Collaborators
  - Alison P. Galvani, Martial L. Ndeffo Mbah, Jeffrey P. Townsend (Yale University)
  - Lauren A. Meyers (University of Texas at Austin)
- Funding
  - Partially funded by NSF grant SBE-0624117